Natural killer cell immune escape in acute myeloid leukemia

被引:0
|
作者
E Lion
Y Willemen
Z N Berneman
V F I Van Tendeloo
E L J Smits
机构
[1] Laboratory of Experimental Hematology,
[2] Vaccine and Infectious Disease Institute (Vaxinfectio),undefined
[3] Faculty of Medicine and Health Sciences,undefined
[4] University of Antwerp,undefined
[5] Center for Cellular Therapy and Regenerative Medicine,undefined
[6] Antwerp University Hospital,undefined
来源
Leukemia | 2012年 / 26卷
关键词
natural killer cells; acute myeloid leukemia (AML); immune escape mechanisms; immunotherapy; NK cell-based immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
As central players of the innate immune system, natural killer (NK) cells can exert direct and indirect anti-tumor effects via their cytotoxic and immune regulatory capacities, pivotal in the induction of an effective adaptive anti-tumor immune response. Hence, NK cells are considered to be important in the immune surveillance of cancer. In acute myeloid leukemia (AML) patients, however, significantly impaired NK cell functions can facilitate escape from immune surveillance and affect patient outcome. Here, we review various NK cell defects and AML evasion mechanisms to escape from NK cell-mediated immune surveillance and we discuss NK cell-related parameters as prediction factors of AML patient outcome. On the basis of these observations, novel immunotherapeutic strategies capitalizing on the potentiation of NK cell functions have emerged in AML immunotherapy, as discussed in this review. Increased knowledge on AML escape routes from NK cell immune surveillance will further aid in the design of novel NK cell-based immunotherapy approaches for the treatment of AML.
引用
收藏
页码:2019 / 2026
页数:7
相关论文
共 50 条
  • [1] Natural killer cell immune escape in acute myeloid leukemia
    Lion, E.
    Willemen, Y.
    Berneman, Z. N.
    Van Tendeloo, V. F. I.
    Smits, E. L. J.
    LEUKEMIA, 2012, 26 (09) : 2019 - 2026
  • [2] Myeloid/natural killer cell acute leukemia.
    Hashimoto, CH
    Etzler, CM
    Peter, JB
    BLOOD, 1999, 94 (10) : 205B - 205B
  • [3] PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia
    Li, Jessica
    Whelan, Sarah
    Kotturi, Maya F.
    Meyran, Deborah
    D'Souza, Criselle
    Hansen, Kyle
    Liang, Spencer
    Hunter, John
    Trapani, Joseph A.
    Neeson, Paul J.
    HAEMATOLOGICA, 2021, 106 (12) : 3115 - 3124
  • [4] Immune escape in acute myeloid leukemia
    Kuzelova, K.
    Brodska, B.
    Otevielova, P.
    Salek, C.
    Gasova, Z.
    Petrackova, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Myeloid/natural killer cell precursor acute leukemia with tetraploidy
    Dinçol, G
    Palandüz, S
    Nalçaci, M
    Uçur, A
    Büyükaydin, B
    CANCER GENETICS AND CYTOGENETICS, 2005, 163 (02) : 156 - 159
  • [6] Dysregulated Activating and Inhibitory Receptors on Natural Killer Cells Predicts Immune Escape and Poor Outcomes in Acute Myeloid Leukemia
    Costa, Amanda F. O.
    Kuznetsova, Valeriya
    Marani, Leticia O.
    Lopes, Izabela A.
    Binelli, Larissa S.
    Scheucher, Priscila S.
    Schiavinato, Josiane L.
    Faria, Joana T. B.
    Madeira, Maria Isabel A.
    Pagnano, Katia B.
    Duarte, Bruno K.
    Gloria, Ana Beatriz F.
    Rego, Eduardo M.
    Traina, Fabiola
    Welner, Robert
    Figueiredo-Pontes, Lorena L.
    BLOOD, 2022, 140 : 9113 - 9114
  • [7] Immune escape and immunotherapy of acute myeloid leukemia
    Vago, Luca
    Gojo, Ivana
    JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04): : 1552 - 1564
  • [8] Myeloid natural killer cell leukemia resembling a variant of acute promyelocytic leukemia
    Burgaleta, C
    de Miguel, D
    Rubio, ML
    Krsnik, I
    Suárez, JG
    HAEMATOLOGICA, 2001, 86 (07) : 765 - 766
  • [9] Impaired Natural Killer Cells Immune Synapse Formation in Acute Myeloid Leukemia
    Xing, Dongxia
    Ramsay, Alan G.
    Decker, William
    Li, Sufang
    Robinson, Simon
    Yang, Hong
    Gribben, John G.
    Shpall, Elizabeth J.
    BLOOD, 2009, 114 (22) : 1044 - 1044
  • [10] Natural killer cell-based immunotherapy for acute myeloid leukemia
    Jing Xu
    Ting Niu
    Journal of Hematology & Oncology, 13